#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3772955	P	Aqueous solubility of the compound at pH 7		9	ALA3769394	small-molecule physicochemical format	Scientific Literature
2.	ALA3772956	B	Inhibition of methyltransferase activity of human EZH2 using chicken oligonucleotide as substrate by pull down assay	Homo sapiens	48	ALA3769394	single protein format	Scientific Literature
3.	ALA3772958	B	Inhibition of methyltransferase activity of EZH2 in human G401 cells assessed as H3K27 trimethylation after 4 hrs by ELISA	Homo sapiens	8	ALA3769394	cell-based format	Scientific Literature
4.	ALA3772959	A	Clearance in mouse at 2 mg/kg, iv and 10 mg/kg, po by LC-MS/MS analysis	Mus musculus	8	ALA3769394	organism-based format	Scientific Literature
5.	ALA3772960	A	AUC in mouse at 2 mg/kg, iv and 10 mg/kg, po by LC-MS/MS analysis	Mus musculus	8	ALA3769394	organism-based format	Scientific Literature
6.	ALA3772961	A	Volume of distribution at steady state in mouse at 2 mg/kg, iv and 10 mg/kg, po by LC-MS/MS analysis	Mus musculus	8	ALA3769394	organism-based format	Scientific Literature
7.	ALA3772962	A	Oral bioavailability in mouse at 10 mg/kg by LC-MS/MS analysis	Mus musculus	8	ALA3769394	organism-based format	Scientific Literature
8.	ALA3772963	B	Inhibition of methyltransferase activity of EZH2 in human lymphoma cells assessed as H3K27 methylation	Homo sapiens	2	ALA3769394	cell-based format	Scientific Literature
9.	ALA3887468	B	Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3.		62	ALA3886332	single protein format	BindingDB Database
10.	ALA3887469	B	Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3.		60	ALA3886332	single protein format	BindingDB Database
11.	ALA3887470	B	Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3.		62	ALA3886332	single protein format	BindingDB Database
12.	ALA3887471	B	Inhibition Assay: Test compounds were serially diluted 3-fold in DMSO in a 10 point-curve and 1 uL was spotted into a 384-well microplate in duplicate using a Platemate Plus equipped with 384-channel head (Thermo Scientific). The final top concentration of test compounds in the assay was 10 uM. Positive control (100% inhibition standard) was 1 mM final concentration of SAH and negative control (0% inhibition standard) contained 1 uL of DMSO. Test compounds were then incubated for 30 minutes with 40 uL per well of wild-type EZH2 (final concentration was 4 nM), Y641F EZH2 (final concentration was 0.1 nM) and A677G and A687V EZH2 (for each, final concentration was 2nM) and peptide in 1x assay buffer (20 mM BICINE pH =7.6, 1 mM DTT, 0.002% TWEEN 20 (generic: polysorbate 20), 0.005% BSG). For the wild-type EZH2 and A677G EZH2 assays, biotinylated peptide H3:21-44 with unmethylated K27 was present at a final concentration of 200 nM, while in the A687V EZH2 assay, biotinylated peptide H3.		62	ALA3886332	single protein format	BindingDB Database
13.	ALA4735334	B	Inhibition of wild type EZH2 in human PRC2 complex using S-adenosylmethionine and biotinylated histone peptides as substrate	Homo sapiens	3	ALA4732117	single protein format	Scientific Literature
14.	ALA5123927	B	Inhibition of PRC2 (unknown origin) assessed as inhibition constant	Homo sapiens	3	ALA5120864	assay format	Scientific Literature